The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Program-non-specific Funding, 2009Time Course of TNF-alpha Expression and Oxidative Stress after Intrastriatal 6-OHDA
Objective/Rationale:
Animal models of Parkinson’s disease can provide investigators with tools to examine the causes of the disease itself as well as potential therapies for treatment. One of the most... -
MJFF Research Grant, 2008Developing New Antibodies for a Standardized Alpha-Synuclein Assay (ELISA)
Objective/Rationale:
To raise and characterize new antibodies in vertebrate animals that allow for the routine measurement of a key protein linked to Parkinson disease, alpha-synuclein. A renewable... -
Rapid Response Innovation Awards, 2008Development of modulators of alpha-synuclein conformation for PD therapeutics
Promising Outcomes of Original Grant:
Our Rapid Response Innovation Award (RRIA) enabled us to develop a conformational change assay for monomeric alpha-synuclein. We identified positive and negative... -
MJFF Research Grant, 2008Pharmacodynamic Biomarkers of Drug-induced Protein Clearance in Rodent Cerebrospinal Fluid
Objective/Rationale:
Parkinson’s disease is, at least in part, a disease caused by misfolding and aggregation of the protein alpha-synuclein. Boosting the natural degradation machinery of diseased... -
Therapeutics Development Initiative -- Academic Track, 2008Novel alpha-Synuclein Isomers as Immunogens for Immunotherapy of Parkinson Diseases
Objective/Rationale:
The excessive accumulation of alpha-synuclein (a normal protein expressed in nervous system) in the brain has been shown to contribute to the pathogenesis of Parkinson disease (PD... -
Therapeutics Development Initiative -- Academic Track, 2008Characterization and validation of C. elegans LRRK2 model of PD
Objective/Rationale:
Autosomal dominant mutations in LRRK2 have been identified as a common cause for late-onset PD. Two of the most frequent PD-causing mutations, G2019S and R1441C, occur within the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.